An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients
Overview
Eosinophils play a key role in the pathogenesis of eosinophilic oesophagitis. Therapies that suppress eosinophil recruitment and activation may give a benefit. Mepolizumab is a humanised monoclonal antibody against interleukin-5 (IL-5). This study will evaluate the ability of mepolizumab to decrease the recruitment and infiltration of eosinophils into the oesophagus, thereby reducing the inflammation and symptoms of EE (eosinophilic oesophagitis) in adult patients.
Full Title of Study: “A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary Evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous Anti-human Interleukin-5 (Mepolizumab, 750mg and 1500mg) in the Treatment of Eosinophilic Oesophagitis in Adults”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Double
- Study Primary Completion Date: March 2007
Interventions
- Drug: mepolizumab
Clinical Trial Outcome Measures
Primary Measures
- 1. Reduction of eosinophils in the oesophagus 2. Safety and tolerability of mepolizumab
Secondary Measures
- 1. Effect of treatment on symptoms, Eosinophil levels, and on inflammation biomarkers in oesophagus tissue and blood.
Participating in This Clinical Trial
Inclusion Criteria
- Document evidence/presence of Oesophagitis prior to commencing trial drug. – a)Histological evidence of Oesophagitis: greater than 20x eosinophils per high power field (X400) on histology of esophageal mucosal biopsy – b. at least one episode of dysphagia per week – c.Inadequate response to routine EE treatment – D. No other known causes of oesophagitis, or esophageal or generalized eosinophilia – Not pregnant or nursing Exclusion criteria:
- History of seasonal worsening of EE symptoms or requirement of Esophageal dilation. – Churg-Strauss Syndrome – Wegener's Granulomatosis – Lymphoma, hematological malignancy, advanced and metastatic solid tumors – Active H. pylori infection. – Any previous treatment with anti-hIL-5, anti-IgE monoclonal antibody or other biological agents.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- GlaxoSmithKline
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- GSK Clinical Trials, Study Director, GlaxoSmithKline
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.